IPO Year: 2021
Exchange: NASDAQ
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4/A - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
10-K/A - Transcode Therapeutics, Inc. (0001829635) (Filer)
DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drugBOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including Nobel Laureate, Dr Phillip
15 patients treated across four escalating dose levels of TTX-MC138No significant safety or dose limiting toxicities reported10 patients remain on study with no evidence of disease progressionPD analysis at 24 hours post-dosing provides evidence of miR-10b target engagementBOSTON, May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Commi
BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on May 15, 2025, under the current trading symbol, "RNAZ." The reverse stock split was approved by TransCode's stockholders and Board of Directors on May 2, 2025, and is intended to increase the per share trading price of
Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
A total of 13 patients treated with four escalating doses of TTX-MC138No significant safety or dose limiting toxicities reportedTwo patients have so far maintained stable disease on treatment for at least seven monthsPD analysis at 24 hours post-dosing provides evidence of miR-10b target engagementBOSTON, May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA wide
BOSTON, April 21, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21, 2025, (the "Special Meeting") has been adjourned until May 2, 2025, at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on April 11, 2025 (the "Special Meeting Proxy Stat
First patient in Cohort four has been treated with TTX-MC138Ten patients have been treated with TTX-MC138 at escalating dose levelsAdditional patients being evaluated for eligibility for expanded enrollmentNo significant safety or dose limiting toxicities have been reportedBOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being e
BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before deducting placement agent fees and offering expenses payable by the Company.
BOSTON, March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the shares of common stock and associated warrants are being offered by the Comp
Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3Patients currently being evaluated for Cohort 4 eligibilityPK and PD data from patients in Cohort 1 and Cohort 2 consistent with preclinical results and results from Phase 0 clinical trialBOSTON, March 13, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimous
SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drugBOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including Nobel Laureate, Dr Phillip
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios. He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approv
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. "We continued to advance our therapeutic programs during the third quarter," said Michael Dudley, co-founder, president and CEO of TransCode. "We remain on track to achieve our planned milestones for 2H of 2022 which include submission of an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial in up to 12 cancer patients with advanced solid tumors. We
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board. "Dr. Slack is one of the most preeminent scientists in the field of small noncoding RNA," commented Zdravka Medarova, PhD, Co-Founder and CTO of TransCode. "Having pioneered pivotal studies proving that microRNAs drive oncogenesis and represent critical targets for the treatment of cancer, his guidance will prove indispensable as TransCode enters the clinical phase of development." Dr. Slack is the Shields Warren Mallinckrodt Profe
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.